Jaguar Health, Inc. current report, 15 December 2017

Full document

Jaguar Health, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Jaguar Health, Inc. on December 18, 2017, regarding events occurring on December 15, 2017. The Company is an emerging growth company incorporated in Delaware. The report details the results of a Special Meeting of Stockholders held on December 15, 2017.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and stockholder voting results rather than financial performance metrics.

Material Changes and Voting Results

Stockholders approved two proposals at the Special Meeting:

  • Proposal 1: Approval of the issuance of up to 17,808,144 shares of common stock to Chicago Venture Partners, L.P. and Iliad Research and Trading, L.P. under the terms of certain promissory notes, pursuant to Nasdaq Listing Rules 5635(b) and (d).
  • Proposal 2: Granting discretionary authority to adjourn the Special Meeting to solicit additional proxies if necessary to approve Proposal 1.

Vote Tally for Proposal 1:

Vote Type Number of Shares
For 23,365,043
Against 1,127,022
Abstained 95,819

Vote Tally for Proposal 2:

Vote Type Number of Shares
For 23,316,512
Against 1,049,391
Abstained 221,981

There were no broker non-votes recorded for either proposal.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure that the issuance of shares is subject to Nasdaq Listing Rules. The details of the promissory notes are referenced as being described in the Company's proxy statement.

Key Facts for Investor Verification

  • Verify the terms of the promissory notes issued to Chicago Venture Partners, L.P. and Iliad Research and Trading, L.P. as referenced in the proxy statement.
  • Confirm the dilution impact of the issuance of up to 17,808,144 new shares of common stock.
  • Review the proxy statement for the Special Meeting for full details on the rationale behind the financing and the specific conditions of the notes.